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Objective: To identify Common Data Elements (CDEs) in eligibility criteria of multiple clinical trials
studying the same disease using a human–computer collaborative approach.
Design: A set of free-text eligibility criteria from clinical trials on two representative diseases, breast can-
cer and cardiovascular diseases, was sampled to identify disease-speciﬁc eligibility criteria CDEs. In this
proposed approach, a semantic annotator is used to recognize Uniﬁed Medical Language Systems
(UMLSs) terms within the eligibility criteria text. The Apriori algorithm is applied to mine frequent dis-
ease-speciﬁc UMLS terms, which are then ﬁltered by a list of preferred UMLS semantic types, grouped by
similarity based on the Dice coefﬁcient, and, ﬁnally, manually reviewed.
Measurements: Standard precision, recall, and F-score of the CDEs recommended by the proposed
approach were measured with respect to manually identiﬁed CDEs.
Results: Average precision and recall of the recommended CDEs for the two diseases were 0.823 and
0.797, respectively, leading to an average F-score of 0.810. In addition, the machine-powered CDEs cov-
ered 80% of the cardiovascular CDEs published by The American Heart Association and assigned by
human experts.
Conclusion: It is feasible and effort saving to use a human–computer collaborative approach to augment
domain experts for identifying disease-speciﬁc CDEs from free-text clinical trial eligibility criteria.
 2012 Elsevier Inc. All rights reserved.1. Introduction
Patient recruitment is essential to successful clinical and trans-
lational research [1]. For this reason, researchers in the biomedical
informatics community developed electronic screening methods
that could increase the efﬁciency of patient recruitment [2,3].
These methods match patients (i.e., prospective research volun-
teers) to the eligibility criteria for clinical trials (e.g., see the follow-
ing systems: caMatch [4], Trialx [5], ResearchMatch [6]). In
common nomenclature, eligibility criteria describe the demographic
and medical characteristics that a research volunteer must possess
to participate in a clinical trial, such as ‘‘body mass index 645 kg/
m2’’ or ‘‘patients with insulin therapy for more than one week
within the 3 months prior to screening’’. However, due to complex-
ities in eligibility criteria [7], this process often returns a set of clin-
ical trials too numerous for patients to identify those for whichll rights reserved.
omedical Informatics, Colum-
ited States. Fax: +1 212 305
ase Western Reserve Univer-they are eligible. For example, at the time of writing, 1091 hyper-
tension and 1021 diabetes trials are actively looking for research
volunteers. Merely knowing that a person has hypertension or dia-
betes is insufﬁcient to include that patient in, or exclude that pa-
tient from a trial. In addition, the trial descriptions are generally
provided in the form of unstructured free text. For example, Clini-
calTrials.gov [8] deﬁnes only a small number of ﬁelds (e.g., ‘‘spon-
sor’’, ‘‘study type’’, ‘‘protocol location’’) for registering trials using
semi-structured summaries; the ‘‘Eligibility Criteria’’ section also
remains largely unstructured.2 Most of the existing clinical trial
search engines often ask questions that are simple and limited in
number (e.g., ‘‘medical conditions’’, ‘‘age’’, ‘‘geographic area’’), a lim-
itation that greatly reduces their speciﬁcity and thus their ability to
retrieve a short list of trials that are manageable to review. There-
fore, ﬁne-grained indexing methods for clinical trial eligibility crite-
ria are required in order to enable accurate and speciﬁc clinical trial
searches [1,9,10].
Clinical trials studying a particular disease often employ com-
mon variables to determine patient eligibility. For example, most
diabetes trials deﬁne inclusion criteria around ‘‘blood glucose le-
vel’’ or ‘‘hemoglobin A1c’’ (i.e., HbA1c), while hypertension trials2 http://www.prsinfo.clinicaltrials.gov/deﬁnitions.html.
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will refer to this kind of variable as a Common Data Element (CDE).
The beneﬁts of using CDEs for clinical trial eligibility criteria in trial
search are well recognized. In fact, CDEs allow users to improve the
speciﬁcity of search results and minimize their need for human re-
view. For example, in Niland’s presentation at the 2007 AMIA
Annual Fall Symposium [11], a user retrieved 28 studies using
the criterion ‘‘having breast cancer’’ alone. When breast cancer eli-
gibility criteria CDEs were added to the query, such as ‘‘estrogen
receptor status’’, ‘‘progesterone receptor status’’, and ‘‘cancer
stage’’, and a user was allowed to specify the threshold value for
these variables, the number of trials retrieved decreased to seven.
Other potential beneﬁts of CDEs include their support for knowl-
edge reuse and sharing of clinical trial eligibility criteria among
investigators [12], as well as simpliﬁcation of trial meta-analysis
[13,14].
CDEs for research data collection have been developed in vari-
ous disease domains [15–19]. Niland, in collaboration with CDISC,
have been using an expert-driven approach to deﬁne ﬁne-grained
eligibility criteria CDEs, which enable highly speciﬁc searches of
cancer trials [11]. However, such manual approaches for CDE iden-
tiﬁcation generally require time-consuming discussions among ex-
perts and work for only one disease at a time [16,19,20]. At the
time of writing, there are 116,728 trials for more than 5000 dis-
eases on ClinicalTrials.gov, making it impossible to manually re-
view all the studies to identify their eligibility criteria CDEs.
Therefore, the human-expert driven approach is not scalable to
the large amounts of data available on this huge repository.
As a consequence, scalable approaches for eligibility criteria
CDE identiﬁcation are greatly needed, even if it is impossible to
fully automate the task with the current technology. On the other
hand, according to Friedman [21], informatics tools should
augment human reasoning rather than replacing domain experts.
With this design principle in mind, this article presents a semi-
automated framework based on text mining that favors human–
computer collaboration and assists users in the identiﬁcation and
reﬁnement of eligibility criteria CDEs. To the best of our knowl-
edge, this is the ﬁrst study exploiting text mining in the task of
CDE discovery from free-text clinical trial eligibility criteria. In bio-
medical research, text mining has been already used to support
knowledge representation and ontology generation [22]; neverthe-
less, current studies in these ﬁelds (e.g., the ‘‘Ontology for Biomed-
ical Investigations (OBIs) [23]’’, the ‘‘Ontology for Clinical Research
(OCRe)’’ [24]) still mostly rely on manual effort for knowledge
acquisition. Conversely, the proposed machine-powered solution
exploits text-based knowledge acquisition and hence could poten-
tially improve the efﬁciency of these projects (e.g., CDE recommen-
dation for expert driven ontology development).
In the following, Sections 2 and 3 present the structure of the
proposed approach and the experimental results, respectively.
The beneﬁts introduced by our method for eligibility criteria CDE
identiﬁcation and current limitations are discussed in Section 4.
Lastly, Section 5 proposes future directions for the work.3 The data were obtained from Clinicaltrials.org in January 2012 using the
‘‘condition’’ ﬁeld to ﬁlter the studies targeting these two diseases. Among all the
trials, we generally retained only those containing a relevant number of eligibility
criteria (e.g., we discarded the trials with zero or one criterion). In addition,
preliminary results not reported here for brevity showed that the machine-powered
approach needs between 1,000 and 3,000 trials to mine relevant CDEs. For this reason,
we set the size of each disease corpus by sampling a number of trials falling within
this interval.2. A semi-automatic approach to derive eligibility criteria CDEs
Fig. 1 illustrates the proposed approach to derive the eligibility
criteria CDEs of any speciﬁc disease from unstructured text, which
speciﬁcally refers to the free-text eligibility criteria available on
ClinicalTrials.gov. As can be seen, eligibility criteria are ﬁrst pro-
cessed to recognize the Uniﬁed Medical Language Systems (UMLS)
entities, which are then analyzed by an association-rule learning
algorithm; the latter mines the CDEs, e.g., ‘‘HbA1C’’ associated with
‘‘diabetes’’ trials. These concepts are later ﬁltered according to pre-
ferred UMLS semantic types, grouped by string similarity, and thenmanually reviewed as CDE candidates. Currently, the approach
only identiﬁes CDEs composed by single UMLS terms.
This study focuses on two diseases only, yet the approach is
general enough to be used for any disease. In particular, we used
a random sample of 1559 breast cancer trials, with a total of
43,084 eligibility criteria, and 2238 cardiovascular disease trials,
with a total of 36,716 criteria.3 We chose these diseases because
there is a large amount of data available online at Clinicaltrials.gov
as well as for the possibility of performing additional comparisons
with manually annotated data (see Section 3.3 for more details).
The following sections present the components of the frame-
work in all the most relevant details.2.1. Semantic annotation
The semantic annotation component tags each free-text eligibil-
ity criterion as a set of UMLS-recognizable terms. When multiple
UMLS terms can be matched, the one that works best in the context
of clinical trials is selected as the preferredmatch in order to reduce
the semantic variety of the criterion itself and to favor its automatic
processing. The annotator was previously described in [25] and, be-
sides tagging the terms using an UMLS-based dictionary, it also ap-
plies a set of semantic preference rules to eliminate the inherent
ambiguity in standard UMLS semantic type assignment. As an
example, the UMLS term ‘‘MRI Scan’’ was assigned only to the
semantic type ‘‘Diagnostic Procedure’’ (CUI-C0024485), which is
more commonly used in clinical trials, discarding other available
options, such as ‘‘Quantitative Concept’’ (CUI-C0917711). The re-
sults reported in [25] shows how this approach achieves results that
are at least as good as those of other solutions, such as MetaMap
[26], in the context of clinical trial eligibility criteria.2.2. Mining the CDEs
The set of UMLS terms from the sample eligibility criteria were
processed by an association rule-learning algorithm to discover the
CDEs associated with each speciﬁc disease. An association rule be-
tween a head X and a body Y is deﬁned as an implication of the
form X) Y. In our domain, X is the set of terms, i.e., X = {x1,
x2, . . . ,xn}, that represents the patient characteristics in disease Y
trials. For example, if X = {insulin, dose} and Y = {diabetes}, then
‘‘insulin’’ and ‘‘dosage of insulin’’ are deﬁned as CDEs for the diabe-
tes trials. In this domain, the support of X, i.e., S(X), is deﬁned as
the number of clinical trials containing the set X (i.e., the probabil-
ity that X is present in the trials of Y). Therefore, the support is cal-
culated by dividing the frequency of X in disease Y trials, by the
total number of such trials.
In order to derive common association rules in the proposed ap-
proach, we used the Apriori algorithm [27], which has been already
successfully employed to extract patterns within clinical variables
[28–31]. The algorithm is based on a bottom-up approach where
frequent patterns are extended one item at a time and groups of
candidates are tested against the data. The algorithm terminates
when no further successful extensions are found. Implementation
is based on breadth-ﬁrst search and hash tree structure to count
candidate patterns efﬁciently. The output is a set of rules (CDEs
in this domain) that reports how often CDEs are present.
UMLS Entity
Identification CDE Mining CDE Filtering
UMLS Semantic
Type SelectionEligibility Criteria
CDE Grouping
Dice Coefficient
Similarity
Review
Knowledge
Engineer
Apriori Algorithm
CDEs
Fig. 1. A human–computer collaborative framework for identifying eligibility criteria CDEs (round-cornered boxes indicate procedures, while rectangle boxes indicate
external resources or algorithms; solid arrows show workﬂow, and dotted arrows indicate information ﬂow).
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search space by exploiting the downward closure property of the
support [27]. In eligibility criteria, this means that if a set of patient
variables is infrequent at a speciﬁc step, then any superset built
upon this set is also considered infrequent. The frequency of a
set is related to the support previously deﬁned. In our implemen-
tation, we tuned the minimum support, expressed as a probability,
equal to 0.001, which implies that in the experimental sample
mentioned above, a set of variables would be kept for further con-
sideration only if the frequency was no less than three (i.e., any set
occurring in less than three trials was ignored in subsequent iter-
ations). This setup allowed us to increase the number and the
diversity of the CDEs while reducing the number of false negatives
(i.e., to reduce the number of true CDEs not correctly recognized).
In addition, we saw empirically that a low threshold value ﬁts the
distribution of eligibility criteria, which is generally a long tail (i.e.,
a small number of CDEs is typically frequent, whereas others are
much less so).
2.3. Filtering the CDEs
With the current setting, the Apriori algorithm returned a large
number of association rules. The latter were then further ﬁltered
and grouped according to semantic similarity. In particular, we
perform two post-processing steps: semantic ﬁltering (see Section
2.3.1) and similarity-based grouping (see Section 2.3.2). One could
argue that ﬁltering and grouping could be performed using the
concept of ‘‘conﬁdence’’, which is a natural measure of the impor-
tance of an association rule [32,33]. In particular, the conﬁdence
score measures the probability of ﬁnding the rule head (i.e., X) of
the association among all the item sets of the data (i.e., the set of
eligibility criteria) containing the rule body (i.e., Y).4 However,
the conﬁdence can be affected by the size of the analyzed data, espe-
cially in presence of very unbalanced sets, i.e., those with a few rule
heads that are frequent and many others that are rare. Moreover, it
does not take into account the role of the terms in the body rules;
therefore, a conﬁdence-based ﬁlter could include highly frequent
terms that are not relevant CDEs (e.g., ‘‘severe’’, ‘‘uncontrolled’’,
‘‘clinically’’). For these reasons, we decided to perform the data ﬁlter-
ing without considering the conﬁdence score of the association rules,
but following the steps described in the next sections.
2.3.1. Semantic ﬁltering
Semantic ﬁltering is a common technique to improve informa-
tion relevance [34]. To this end, we used as our information ﬁlter
a preference list of semantic types that are common in eligibility
criteria. In particular, previous studies [35,36] deﬁned 27 semantic
classes for clinical trial eligibility criteria at the sentence level, e.g.,
‘‘Disease or Symptom’’, ‘‘Therapy or Surgery’’, ‘‘Diagnostic or Lab
Results’’, each containing a set of frequent UMLS semantic types.
Overall we manually selected 48 semantic classes to be used as4 The conﬁdence C of an association rule XY is computed using the concept of
support introduced in Section 2.2; in particular, C = S(XUY)/S(X).groups and ﬁlters for CDEs (see Appendix 1). For example, the
semantic class ‘‘Diagnostic or Lab Results’’ grouped the UMLS
semantic types ‘‘Laboratory Procedure’’ and ‘‘Laboratory or Test Re-
sults’’. Therefore, the UMLS terms associated with these semantic
types were designated as CDEs under the same semantic class.
2.3.2. Grouping similar CDEs using dice coefﬁcient
The list of raw CDEs returned by the Apriori algorithm was ran-
domly ranked. As a result, similar CDEs, e.g., ‘‘urine pregnancy
test’’, ‘‘pregnancy test’’, were often not adjacent, complicating the
manual review process. Therefore, in order to return a list of CDEs
ranked by some criterion of correlation, we applied the Dice Coef-
ﬁcient (DC) to measure the similarity between pairs of strings and
created a list of CDEs ranked according to this measure.
The Dice coefﬁcient of two strings i and j represented as bi-
grams is deﬁned as
DC ¼ 2Nij
NiNj
;
where Nij is the number of bigrams in common between the two
strings, and Ni and Nj are the number of bigrams for strings i and
j, respectively [37].
The large number of terms extracted from the eligibility criteria
made it computationally impracticable to calculate all the pair-
wise similarity values. For this reason we used an iterative greedy
search strategy [38], which starts by assigning the highest ranking
to the term with the largest support, i.e., the ‘‘seed’’ term. At each
iteration, the algorithm looks for the next term having the largest
DC-based similarity with the current seed, adds this term to the
ranking list, and makes it the new seed. The process repeats until
all terms are sorted.
The result of grouping can be seen in Table 1. First, before
grouping, CDEs are only tagged using the UMLS semantic types
and returned in a random order (left part). Afterwards, CDEs are
grouped not only by semantic type, but also by disease topic (right
part, where groups are highlighted using marking symbols (i.e., ⁄,
+, ^, ). The grouping assists manual review of the CDEs by pre-
senting to the user semantically related concepts. In fact, in this
case a user can easily see that the CDEs fall into four distinct
groups: hepatic disease, heart disease, breast cancer, and function
impairment.
3. Experimental results
This section presents the results achieved by applying the pro-
posed approach to derive CDEs for the two diseases considered,
breast cancer and cardiovascular diseases.
3.1. Examples of machine-powered eligibility criteria CDEs
First, we report a sample of the CDEs mined by the proposed
semi-automatic approach. In particular, Table 2 shows the top ﬁve
CDEs retrieved with respect to the four most frequent semantic
classes for both diseases: ‘‘Disease, Symptom and Sign’’, ‘‘Diagnos-
Table 1
Eligibility criteria CDEs as presented to the user by the Apriori
algorithm (left) and after Dice Coefﬁcient-based (DC) grouping
(right). In the tables: DSNY = ‘‘Disease_or_Syndrome’’; NEOP =
‘‘Neoplastic_Process’’; (⁄, +, ^, ) mark groups of semantically
related data.
Type Apriori algorithm list
DSNY Coronary heart disease (+)
DSNY Hepatic disease (⁄)
DSNY Hepatitis c (⁄)
NEOP Invasive carcinoma of the breast ()
DSNY Hepatic disease (⁄)
NEOP Breast adenocarcinoma ()
DSNY Hearing impairment (^)
DSNY Heart disease (+)
DSNY Cognitive impairment (^)
DSNY Hepatic cirrhosis (⁄)
NEOP Breast carcinoma ()
DSNY Hepatitis b (⁄)
DSNY Heart attack (+)
DSNY Coronary artery disease (+)
DSNY Visual impairment (^)
NEOP Recurrent breast cancer ()
NEOP Invasive breast cancer ()
NEOP Stage iv breast cancer ()
DSNY Renal impairment (^)
DC-based grouped list
DSNY Hepatitis b (⁄)
DSNY Hepatitis c (⁄)
DSNY Hepatic cirrhosis (⁄)
DSNY Heart disease (+)
DSNY Coronary heart disease (+)
DSNY Coronary artery disease (+)
DSNY Heart attack (+)
DSNY Renal impairment (^)
DSNY Visual impairment (^)
DSNY Hearing impairment (^)
DSNY Cognitive impairment (^)
NEOP Breast adenocarcinoma ()
NEOP Breast carcinoma ()
NEOP Invasive carcinoma of the breast ()
NEOP Invasive breast cancer ()
NEOP Stage iv breast cancer ()
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and ‘‘Therapy or Surgery’’. As can be seen, in most cases, our meth-
od led to pertinent CDEs. In fact, considering the breast cancer do-
main as an example, common variables mined by the algorithm are
‘‘chemotherapy’’, ‘‘radiotherapy’’, and ‘‘hormonal therapy’’, which
are well-known cancer therapies, as well as ‘‘IHC’’ (i.e., Immuno-
HistoChemistry) [39] and ‘‘Platelet Count’’ (an indicator of the side
effect of breast cancer treatments), which are frequent measures
reported in related laboratory results.3.2. Retrieval results
We evaluated the correctness of the CDEs recommended by the
proposed approach by comparing them with CDEs independently
identiﬁed by the authors. Our manual identiﬁcation process con-
tained two steps: (1) list all the terms and their frequencies; and
(2) manually review all these terms and retain only those that
(a) occur at least three times (as the minimum support threshold
deﬁned in Section 2.2); (b) specify one patient characteristic. We
used the standard information retrieval metrics precision, recall,
and F-score [40]. Precision is the probability that the approach cor-
rectly retrieves a CDE. Recall is the probability that the approach
retrieves a CDE that should have been retrieved. F-score is the har-
monic mean of precision and recall and is a single measure of the
overall retrieval performance. The results, reported in Table 3,
demonstrate that the proposed approach has a high recall value,
correctly identifying 80% of all the CDEs retrieved by manualreview. The average precision across both diseases was 0.823, indi-
cating that this method has a false positive rate of less than 20%.
Finally, the resulting average F-score was 0.810. All the CDEs iden-
tiﬁed by the machine-powered approach and by the experts are re-
ported in Appendices 2 and 3 for cardiovascular diseases and
breast cancer, respectively.3.3. Comparison with expert-deﬁned CDEs
The American College of Cardiology Foundation (ACCF) and the
American Heart Association (AHA) recently published 95 key car-
diovascular disease CDEs deﬁned by human experts [16]. For com-
parison, we evaluated how the cardiovascular CDEs mined by our
approach were represented with respect to this standard. As Table
4 shows, the mined CDEs covered about 80% of the CDEs deﬁned by
the ACCF/AHA standard. The latter classiﬁes all the data elements
into ﬁve categories: we achieved the best coverage in the category
‘‘History and Physical Examinations’’ (e.g., ‘‘chest pain’’, ‘‘angina
grade’’) with 89.2% and in ‘‘Pharmacologic Therapies’’ (e.g., ‘‘Aspi-
rin and steroid’’) with 85.7%. The coverage in the other categories
was lower: in particular, we achieved the ‘‘Laboratory Results’’,
the ‘‘Diagnostic and Therapeutic Procedures’’, and the ‘‘Outcomes’’
covered at about 73%, 67%, and 50%, respectively. It should be
noted that the ‘‘Outcomes’’ comprised only two elements:
‘‘Death’’ and ‘‘Date of Death’’. Our system correctly identiﬁed
the former.
The proposed approach also identiﬁed some CDEs that were not
formally deﬁned by the ACCF/AHA standard. For example, Table 5
shows all the medication CDEs that the machine-powered ap-
proach found with a frequency greater than 10 that were not de-
ﬁned in the ACCF/AHA standard; many of these are common
treatments for cardiovascular diseases. Therefore, the machine-
powered approach might have the potential to augment human-
based CDEs with additional knowledge. Lastly, Appendix 4 lists
the comparison between the machine-recommended CDEs and
the CDEs published by AHA.4. Discussion
This section provides an analysis on the strengths (Section 4.1)
and limitations (Section 4.2) of the proposed approach.4.1. Advantages over related approaches to CDE development
The human expert-based CDE development process consists of
six steps: (1) reviewing data sources and existing standards; (2)
generating CDE candidates; (3) prioritizing CDEs; (4) deﬁning attri-
butes and valid values for each CDE; (5) convening group discus-
sions to achieve consensus deﬁnitions; and (6) eliciting peer
reviews and applying for board approvals. Each step requires sig-
niﬁcant time from multidisciplinary domain experts, from several
weeks to several months [15,16,18,20]. The machine-powered ap-
proach can reduce the time required for domain experts on steps 1,
2, 3, and 5.
First, the existing manual CDE selection method heavily relies
on domain experts in identifying CDE candidates. For example, in
the ACCF/AHA standard, an informatics committee identiﬁed a pre-
liminary set of candidate CDEs through face-to-face and conference
call meetings, as well as email correspondence. This is a labor-
intensive process and, in fact, the experts spent more than
6 months merely reﬁning and vetting a list of candidate CDEs.
Because our method recommends CDEs through text mining, it sig-
niﬁcantly reduces the need to manually review large amount of
text.
Table 2
The top ﬁve CDEs in the four most frequent semantic classes for breast cancer and cardiovascular diseases.
Target disease therapy or surgery UMLS concept ID Top 5 CDEs Frequency
C0392920 Chemotherapy 323
Breast cancer trials C0034619 Radiotherapy 98
C0279025 Hormonal therapy 80
C0034619 Radiation therapy 55
C0175795 Oral medication 54
Cardiovascular disease trials C1532338 PCI (percutaneous coronary intervention) 747
C0581603 Revascularization 350
C0010055 CABG (coronary artery bypass surgery) 330
COO11946 dialysis 234
C0162589 ICD (implantable cardioverter deﬁbrillator) 224
Diagnostic or lab results
C0021044 IHC (immune histo chemistry) 1194
Breast cancer trials C0032181 Platelet count 776
C0373595 creatinine clearance 739
C0428772 LVEF (left ventricular ejection fraction) 604
C0201976 serum creatinine 441
Cardiovascular disease trials C0428772 LVEF (left ventricular ejection fraction) 811
C0201976 Serum creatinine 585
C0032181 Platelet count 166
C0027051 Stemi (myocardial infarction) 143
C0302353 Serum_potassium 104
Medication
C0002059 Alkaline_phosphatase 696
Breast cancer trials C0728747 Trastuzumab 208
C0039286 Tamoxifen 85
C0215136 Taxane 61
C0014939 Estrogen 49
Cardiovascular disease trials C0360714 Statin 240
C0003195 Antiarrhythmic 110
C0004057 Aspirin 102
C0070166 Clopidogrel 100
C0144576 Paclitaxel 100
Disease, symptom and sign
C0006142 Breast cancer 1873
Breast cancer trials C2939420 Metastatic disease 681
C0278488 Metastatic breast cancer 316
C0494165 Liver metastases 205
C0858252 Adenocarcinoma of the breast 108
Cardiovascular disease trials C0027051 Myocardial infarction 1706
C0020538 Hypertension 1552
COO18801 Heart failure 1061
C0002962 Angina 897
C0022116 Ischemia 799
Table 3
Retrieval results in terms of precision (P), recall (R), and F-score for the CDE identiﬁcation in the two disease domains, i.e., breast cancer, cardiovascular diseases. In the table:
TP = ‘‘true positives’’, FN = ‘‘false negatives’’, TN = ‘‘true negatives’’, FP = ‘‘false positives’’.
Diseases Clinical trials
count
Criteria sentences
(Inclusion)
Machine
powered CDEs
Human
based CDEs
TP FN TN FP P R F-score
Breast cancer 849 8616 808 829 677 152 2630 131 0.838 0.817 0.827
Cardiovascular diseases 976 8285 641 668 519 149 2094 124 0.807 0.777 0.792
Average 0.823 0.797 0.810
Table 4
Coverage of the machine-powered CDEs with respect to the ACCF/AHA standard for the cardiovascular diseases. In the table, coverage is deﬁned as Machine/(ACCF/AHA).
CDE Source Examination Laboratory Diagnosis Pharmacologic Outcome Total
ACCF/AHA 37 11 24 21 2 95
Machine 33 8 16 18 1 76
Coverage (%) 89.2 72.7 66.7 85.7 50.0 80.0
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tion regarding the representativeness of the CDEs within the data.
For example, in order to prioritize CDEs of Atrial Fibrillation [41],
the ACC/AHA committee spent several months on manually
reviewing literature and trials data source. They classiﬁed CDEs
by frequency into only three very broad categories: ‘‘high’’, ‘‘med-ium’’, and ‘‘low’’. Conversely, the machine-powered approach
provides a statistical evaluation about the role of CDEs among
the various trials, which can be used in many ways. For example,
the frequency information may inform trial eligibility criteria
authors about the uses of CDEs in the past and their prevalence
in a particular disease. It also may help researchers to develop
Table 5
List of medication CDEs that are not listed in the ACCF/AHA standard but are correctly
found by the machine-powered approach. In the table, CUI = ‘‘Concept Unique
Identiﬁer’’.
UMLS CUI Medication CDEs Frequency
C0070166 Clopidogrel 100
CO144576 Paclitaxel 100
C0019134 Heparin 79
C0003195 Antiarrhythmic drug 74
C0040207 Ticlopidine 70
C0043031 Warfarin 52
C0699493 Luminal 43
C0521942 Angiotensin ii receptor antagonist 37
C0600437 Nitric oxide donors 37
C0002598 Amiodarone 19
COO12963 Dobutamine 19
C0001443 Adenosine 19
COO17887 Nitro glycerin 16
C0541315 Everolimus 16
C0003364 Antihypertensive 13
C0003280 Anticoagulant 12
COO17725 Glucose 12
COO12265 Digoxin 11
C0001617 Corticosteroids 10
C0001480 Atp 10
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ual effort needed to rank them.
Manually reviewing the CDEs also requires searching medical
terminologies and existing data standards. In our approach, the
CDE candidates are automatically annotated with UMLS concept
ID and semantic types, and the term list is sorted to allow the user
fast browsing and generalization. As a result, domain experts can
start directly from the proposed CDE candidates to select and
formally deﬁne CDE attributes. Therefore, the machine-powered
approach has the potential to reduce the time required for clinical
experts to reach a consensus.
Finally, due to the limitations of expertise specialization and
time constraints, it is difﬁcult to develop CDE candidates across a
large number of different diseases. This is the main reason that
existing CDE development efforts focus on one disease at a time.
This is a signiﬁcant barrier to achieving one of the major goals of
CDE development, the support of large-scale data aggregation for
research and discovery. In contrast, the machine-powered ap-
proach attempts to surmount this by making use of an unsuper-
vised machine learning algorithm and, consequently, of a general
solution. In fact, in order to work with other diseases, the approach
requires only the disease name (or code) and source of information
to automatically retrieve the corresponding clinical trials, parse the
eligibility criteria section, and return the CDEs.4.2. Limitations
At this point, there are two major limitations about this ap-
proach. First, some false positives were due to verbs (e.g., ‘‘sche-
dule’’, ‘‘repair’’). However, they do not describe patient
characteristics and should not be classiﬁed as CDEs. We hypothe-
size that the use of part-of-speech analysis [42] may be able to ﬁl-
ter this type of false positive.
Second, multi-term CDEs such as ‘‘[patient’s] age at diagnosis’’
and ‘‘[patient’s] age at death’’ contain multiple UMLS terms. At this
point, our system is able to identify ‘‘age’’ as an eligibility criterion
CDE but cannot capture CDEs including multiple UMLS terms and,
therefore, cannot distinguish ‘‘age of diagnosis’’ and ‘‘age of death’’.
In this case, we still rely on domain experts to group UMLS terms to
form more meaningful CDEs. However, this aspect of design is
impractical, and therefore temporary, because it reduces the scala-bility of the approach, especially with respect to the number of dis-
eases that can be processed.
5. Conclusion
This paper contributes a scalable human–computer collabora-
tive approach to CDE identiﬁcation, which combines the use of
an unsupervised machine learning algorithm (i.e., association
rule-learning) with UMLS to process the free-text eligibility criteria
associated with the clinical trials of a speciﬁc disease. The accuracy
achieved in this initial study using two diseases, i.e., breast cancer
and cardiovascular diseases, and ClinicalTrials.gov as data source is
satisfactory and promising. The approach is only semi-automated,
so that domain experts are still required for reviewing, ﬁltering,
and enriching the recommended CDEs. On the other hand, the ma-
chine-recommended CDEs reduce the workload of the experts,
who no longer have to manually parse a large number of clinical
research documents.
Future studies can focus on the following aspects. First, the
semantic annotator plays a key role in CDE identiﬁcation and re-
quires improvements to accommodate the continual data updates
on ClinicalTrials.gov. Second, the approach should be extended to
identify multi-term CDEs to improve the overall machine perfor-
mance. Third, organizing and formatting the CDEs (e.g., structuring
them into ontologies) would enable interoperability. Last, this ini-
tial study focused only on CDE identiﬁcation, not on CDE deﬁnition.
The latter involves CDE attribute speciﬁcation and feature discov-
ery and is an important and advanced research topic on its own
for semi-automated CDE discovery.
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